This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed? Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 ...
A panelist highlights promising early-phase trial data on trispecific antibodies targeting multiple myeloma antigens and CD3, emphasizing their high response rates, manageable safety profiles, and ...
Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results